Department of Cardiology, Renmin Hospital of Wuhan University; Cardiovascular Research Institute, Wuhan University; Hubei Key Laboratory of Cardiology, Wuhan, Hubei, China.
Heart Rhythm Institute and Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
JACC Cardiovasc Interv. 2017 Aug 14;10(15):1511-1520. doi: 10.1016/j.jcin.2017.04.036.
The aim of this study was to investigate whether low-level tragus stimulation (LL-TS) treatment could reduce myocardial ischemia-reperfusion injury in patients with ST-segment elevation myocardial infarction (STEMI).
The authors' previous studies suggested that LL-TS could reduce the size of myocardial injury induced by ischemia.
Patients who presented with STEMI within 12 h of symptom onset, treated with primary percutaneous coronary intervention, were randomized to the LL-TS group (n = 47) or the control group (with sham stimulation [n = 48]). LL-TS, 50% lower than the electric current that slowed the sinus rate, was delivered to the right tragus once the patients arrived in the catheterization room and lasted for 2 h after balloon dilatation (reperfusion). All patients were followed for 7 days. The occurrence of reperfusion-related arrhythmia, blood levels of creatine kinase-MB, myoglobin, N-terminal pro-B-type natriuretic peptide and inflammatory markers, and echocardiographic characteristics were evaluated.
The incidence of reperfusion-related ventricular arrhythmia during the first 24 h was significantly attenuated by LL-TS. In addition, the area under the curve for creatine kinase-MB and myoglobin over 72 h was smaller in the LL-TS group than the control group. Furthermore, blood levels of inflammatory markers were decreased by LL-TS. Cardiac function, as demonstrated by the level of N-terminal pro-B-type natriuretic peptide, the left ventricular ejection fraction, and the wall motion index, was markedly improved by LL-TS.
LL-TS reduces myocardial ischemia-reperfusion injury in patients with STEMI. This proof-of-concept study raises the possibility that this noninvasive strategy may be used to treat patients with STEMI undergoing primary percutaneous coronary intervention.
本研究旨在探讨低位耳屏刺激(LL-TS)治疗是否可减轻 ST 段抬高型心肌梗死(STEMI)患者的心肌缺血再灌注损伤。
作者先前的研究表明,LL-TS 可减轻缺血引起的心肌损伤程度。
本研究纳入发病 12 h 内接受直接经皮冠状动脉介入治疗的 STEMI 患者,随机分为 LL-TS 组(n=47)和对照组(假刺激组,n=48)。患者到达导管室后即给予右侧耳屏 50%低于窦性心动过缓电流的 LL-TS 刺激,持续 2 h 至球囊扩张(再灌注)后结束。所有患者均随访 7 天。评估再灌注相关心律失常的发生情况、肌酸激酶同工酶-MB、肌红蛋白、氨基末端 B 型利钠肽原和炎症标志物的血水平以及超声心动图特征。
LL-TS 可显著减轻前 24 h 内再灌注相关室性心律失常的发生。此外,LL-TS 组的肌酸激酶同工酶-MB 和肌红蛋白在 72 h 内的曲线下面积均小于对照组。此外,LL-TS 降低了炎症标志物的血水平。LL-TS 还明显改善了氨基末端 B 型利钠肽原、左心室射血分数和室壁运动指数等指标所代表的心脏功能。
LL-TS 可减轻 STEMI 患者的心肌缺血再灌注损伤。这项概念验证研究提示,这种非侵入性策略可能用于治疗接受直接经皮冠状动脉介入治疗的 STEMI 患者。